The pharmacoeconomic analysis compared the strategies of arterial hypertension (AH) management using different angiotensin II receptor blockers (ARB). The first stage of the analysis included the cost-effectiveness modelling in patients with moderate AH receiving olmesartan, losartan, or valsartan. As the second stage, a similar analysis was performed for patients with moderate AH and diabetes mellitus (DM) or renal failure. Clinical and economic benefits were demonstrated for olmesartan,

more »

... ed to losartan or valsartan. The cost-effectiveness ratio was minimal for olmesartan therapy in patients with both moderate AH and a combination of moderate AH and DM or renal failure. Therefore, olmesartan should be considered as a first-choice medication while selecting the optimal clinical and pharmacoeconomic strategy of AH management with ARB.